Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10826-10833

  Kuniholm, Mark H ^a   Gao, Xiaojiang ^b,c   Xue, Xiaonan ^a   Kovacs, Andrea ^d   Anastos, Kathryn ^a,e   Marti, Darlene ^b,c   Greenblatt, Ruth M ^f   Cohen, Mardge H ^g   Minkoff, Howard ^h   Gange, Stephen J ⁱ   Fazzari, Melissa ^a   Young, Mary A ^j   Strickler, Howard D ^a   Carrington, Mary ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b SAIC FREDERICK INC   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Cook County Bureau of Health Services ^*  (United States)

^h MAIMONIDES MEDICAL CENTER   (United States)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^j GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ENFUVIRTIDE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MARAVIROC; RALTEGRAVIR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; GENOTYPE; HIV INFECTIONS; HLA ANTIGENS; HUMANS; VIRAL LOAD;

EID: 80055003489     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00804-11     Document Type: Article

References (40)

1. Ahdieh, L., et al. 2000. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am. J. Epidemiol. 152:923-933.
2. Ahuja, S. K., et al. 2008. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14:413-420.
3. Al-Harthi, L., et al. 2006. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/ HIV-coinfected women: role of HCV on expression of primed/memory T cells. J. Infect. Dis. 193:1202-1210.
4. Anonymous. 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recommend. Rep. 41(RR-17):1-19.
5. Barkan, S. E., et al. 1998. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 9:117-125.
6. Brumme, Z. L., et al. 2008. Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J. Virol. 82:9216-9227.
7. Brumme, Z. L., et al. 2007. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J. Infect. Dis. 195:1694-1704.
8. Calvelli, T., T. N. Denny, H. Paxton, R. Gelman, and J. Kagan. 1993. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 14:702-715.
9. Carrington, M., M. P. Martin, and J. van Bergen. 2008. KIR-HLA intercourse in HIV disease. Trends Microbiol. 16:620-627.
10. Carrington, M., et al. 1999. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283:1748-1752.
11. Carrington, M., and S. J. O'Brien. 2003. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54:535-551.
12. Chen, T. Y., E. L. Ding, G. R. Seage Iii, and A. Y. Kim. 2009. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin. Infect. Dis. 49:1605-1615.
13. Cook, J. A., et al. 2002. Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am. J. Public Health 92:82-87.
14. Flores-Villanueva, P. O., et al. 2001. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl. Acad. Sci. U. S. A. 98:5140-5145.
15. Gao, X., et al. 2001. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344:1668-1675.
16. Gazzola, L., C. Tincati, G. M. Bellistri, A. Monforte, and G. Marchetti. 2009. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin. Infect. Dis. 48:328-337.
17. Gianella, S., and D. D. Richman. 2010. Minority variants of drug-resistant HIV. J. Infect. Dis. 202:657-666.
18. Goulder, P. J., and D. I. Watkins. 2008. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8:619-630.
19. Grabar, S., et al. 2000. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133:401-410.
20. Hernan, M. A., S. Hernandez-Diaz, and J. M. Robins. 2004. A structural approach to selection bias. Epidemiology 15:615-625.
21. Hirsch, M. S., et al. 2008. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society- U. S. A. panel. Clin. Infect. Dis. 47:266-285.
22. Kaslow, R. A., M. T. Dorak, and J. J. Tang. 2001. Is protection in HIV infection due to Bw4 or not to Bw4? Lancet Infect. Dis. 1:221-222.
23. Kemal, K. S., et al. 2007. HIV-1 drug resistance in variants from the female genital tract and plasma. J. Infect. Dis. 195:535-545.
24. Khakoo, S. I., et al. 2004. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305:872-874.
25. Kiepiela, P., et al. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432:769-775.
26. Kuniholm, M. H., et al. 2010. Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology 51:1514-1522.
27. Kuo, C. L., and E. Feingold. 2010. What's the best statistic for a simple test of genetic association in a case-control study? Genet. Epidemiol. 34:246-253.
28. Lima, V. D., R. S. Hogg, and J. S. Montaner. 2007. Presenting plasma HIV RNA level and rate of CD4 T-cell decline. JAMA 297:805-806.
29. Mallal, S., et al. 2002. Association between presence of HLA-B*5701, HLADR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-732.
30. Martin, M. P., et al. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31:429-434.
31. Minkoff, H., et al. 2010. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J. Infect. Dis. 201:681-690.
32. Moore, D. M., et al. 2005. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J. Acquir. Immune. Defic. Syndr. 40:288-293.
33. Nguyen, L., et al. 2004. Frequent human leukocyte antigen class I alleles are associated with higher viral load among HIV type 1 seroconverters in Thailand. J. Acquir. Immune. Defic. Syndr. 37:1318-1323.
34. Philpott, S., et al. 2005. Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination. J. Virol. 79:353-363.
35. Rauch, A., et al. 2008. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin. Infect. Dis. 46:1921-1925.
36. Rodriguez, B., et al. 2006. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296:1498-1506.
37. Schneider, M. F., et al. 2005. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 19:2009-2018.
38. Strickler, H. D., et al. 2008. Associations of insulin-like growth factor (IGF)-I and IGF-binding protein-3 with HIV disease progression in women. J. Infect. Dis. 197:319-327.
39. Tang, J., et al. 1999. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 15:317-324.
40. Trachtenberg, E., et al. 2003. Advantage of rare HLA supertype in HIV disease progression. Nat. Med. 9:928-935.